Regulus Therapeutics
Stock Forecast, Prediction & Price Target
Regulus Therapeutics Financial Estimates
Regulus Therapeutics Revenue Estimates
Regulus Therapeutics EBITDA Estimates
Regulus Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $44.16M Low: $44.16M High: $44.16M avg. 0% | Avg: $176.76M Low: $176.76M High: $176.76M avg. 300.19% | Avg: $332.6M Low: $332.6M High: $332.6M avg. 88.16% |
Net Income
% change YoY
| $-27.80M N/A | $-28.32M -1.85% | $-30.03M -6.05% | Avg: $-48.90M Low: $-15.35M High: $-13.65M avg. -62.82% | Avg: $-58.85M Low: $-17.25M High: $-12.89M avg. -20.33% | Avg: $6.12M Low: $6.12M High: $6.12M avg. 110.40% | Avg: $35.64M Low: $35.64M High: $35.64M avg. 482.13% |
EBITDA
% change YoY
| $-27.81M N/A | $-28.23M -1.52% | $-30.88M -9.35% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $8.83M Low: $8.83M High: $8.83M avg. 0% | Avg: $35.35M Low: $35.35M High: $35.35M avg. 300.19% | Avg: $66.51M Low: $66.51M High: $66.51M avg. 88.16% |
EPS
% change YoY
| -$3.24 N/A | -$1.86 42.59% | -$1.58 15.05% | Avg: -$0.77 Low: -$0.81 High: -$0.72 avg. 51.58% | Avg: -$0.8 Low: -$0.91 High: -$0.68 avg. -3.92% | Avg: $0.32 Low: $0.32 High: $0.32 avg. 140.62% | Avg: $1.88 Low: $1.88 High: $1.88 avg. 482.13% |
Operating Expenses
% change YoY
| $27.81M N/A | $28.23M 1.52% | $9.95M -64.74% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $48.91M Low: $48.91M High: $48.91M avg. 0% | Avg: $195.75M Low: $195.75M High: $195.75M avg. 300.19% | Avg: $368.34M Low: $368.34M High: $368.34M avg. 88.16% |
FAQ
What is Regulus Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 127.34% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -15.35M, average is -48.90M and high is -13.65M.
What is Regulus Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 97.09% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Regulus Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 167.60% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.81, average is -$0.77 and high is $-0.72.